StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3085% above fair value
$13.45+0.12 (+0.90%)

Close on Nov 19, 2026Market cap $471.65MP/E –Yield –

Fennec Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2013 it was -$2.21M.

Annual free cash flow

PeriodPeriod endValueChange
FY2013Dec 31, 2013-$2.21M–
FY2012Dec 31, 2012-$2.99M–
FY2011Dec 31, 2011-$3.23M–

More Fennec Pharmaceuticals figures

See a number that looks wrong?